Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations.

Blum S, Martins F, Alberio L.

J Blood Med. 2016 Sep 23;7:205-215. Review.

2.

Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera.

Raedler LA.

Am Health Drug Benefits. 2015 Mar;8(Spec Feature):75-9. No abstract available.

3.

Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.

Raedler LA.

Am Health Drug Benefits. 2014 Oct;7(7 Suppl 3):S36-47. No abstract available.

4.

Diagnostic testing managed by hematopathology specialty and other laboratories: costs and patient diagnostic outcomes.

Engel-Nitz NM, Eckert B, Song R, Koka P, Hulbert EM, McPheeters J, Teitelbaum A.

BMC Clin Pathol. 2014 Apr 27;14:17. doi: 10.1186/1472-6890-14-17.

5.

Essential thrombocythemia: a rare disease in childhood.

Beatrice JM, Garanito MP.

Rev Bras Hematol Hemoter. 2013;35(4):287-9. doi: 10.5581/1516-8484.20130059.

6.

Myeloid neoplasms in the guise of nutritional deficiency.

Parthasarathy V.

Case Rep Hematol. 2012;2012:826939. doi: 10.1155/2012/826939.

7.

The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia.

Conchon M.

Rev Bras Hematol Hemoter. 2011;33(6):401-2. doi: 10.5581/1516-8484.20110110. No abstract available.

8.

Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.

Mascarenhas J, Mughal TI, Verstovsek S.

Curr Med Chem. 2012;19(26):4399-413. Review.

9.

Concurrent stenoocclusive disease of intracranial and extracranial arteries in a patient with polycythemia vera.

Hua le H, Dodd RL, Schwartz NE.

Case Rep Med. 2012;2012:151767. doi: 10.1155/2012/151767.

Supplemental Content

Support Center